GHDX - Genomic Health, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+2.23 (+4.28%)
As of 3:30PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close52.10
Bid54.16 x 900
Ask54.20 x 800
Day's Range52.63 - 55.53
52 Week Range48.72 - 92.18
Avg. Volume544,171
Market Cap2.014B
Beta (3Y Monthly)1.31
PE Ratio (TTM)49.03
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Hedge Funds Have Never Been This Bullish On Genomic Health, Inc. (GHDX)
    Insider Monkey7 days ago

    Hedge Funds Have Never Been This Bullish On Genomic Health, Inc. (GHDX)

    Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]

  • Why Is Genomic Health (GHDX) Down 5% Since Last Earnings Report?
    Zacks12 days ago

    Why Is Genomic Health (GHDX) Down 5% Since Last Earnings Report?

    Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Calculating The Intrinsic Value Of Genomic Health, Inc. (NASDAQ:GHDX)
    Simply Wall St.13 days ago

    Calculating The Intrinsic Value Of Genomic Health, Inc. (NASDAQ:GHDX)

    Today we will run through one way of estimating the intrinsic value of Genomic Health, Inc. (NASDAQ:GHDX) by taking...

  • Here's Why Genetic Testing Stocks Lost as Much as 26.1% in May
    Motley Fool14 days ago

    Here's Why Genetic Testing Stocks Lost as Much as 26.1% in May

    Wall Street soured on the high-growth industry after first-quarter earnings were reported, but it may have been an overreaction for two stocks.

  • 3 Cancer Treatment Stocks to Buy Right Now
    Motley Fool26 days ago

    3 Cancer Treatment Stocks to Buy Right Now

    These companies could make a big difference in how the disease is diagnosed and treated. And their stocks could make a big difference for long-term investors.

  • The 1 Stock I'd Buy Right Now
    Motley Fool27 days ago

    The 1 Stock I'd Buy Right Now

    The genetic testing industry is still in its infancy, but this leader is comfortably profitable and growing at a healthy clip.

  • 7 A-Rated Healthcare Stocks for Industry Expansion
    InvestorPlace29 days ago

    7 A-Rated Healthcare Stocks for Industry Expansion

    According to the Centers for Medicare and Medicaid Services, healthcare spending will rise 5.5% annually through 2026, when that spending will represent 20% of the country's GDP; a boon for healthcare stocks.To put this in perspective, the U.S. defense budget is about 18% of the entire U.S. budget and we outspend every other nation on this planet in defense spending by a significant margin.The U.S. healthcare system is being debated again and may well be a significant issue in the upcoming presidential election.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut the reality is, the U.S. population is getting older and that means more chronic diseases begin to take their toll. Also, older people tend to take up a larger portion of healthcare costs as their health begins to fail. * 7 High-Yield REITs to Buy (Even When the Market Tanks) That means there will be an unstoppable growth trend in place for healthcare companies. The A-rated healthcare stocks I feature here are well placed to take advantage of this trend. And they're small enough that their growth will outpace their larger competitors and may make them interesting takeover targets.Source: Flickr Masimo (MASI)Masimo Corp (NASDAQ:MASI) is the perfect example of how technology is transforming healthcare.Once, heading the doctors or the hospital was a regular occurrence for patients with chronic issues like heart disease or diabetes. But now, monitoring technologies, where patients can wear a device that essentially tracks their functions and the data can either be downloaded remotely or by the patient and sent to the doctor, are becoming increasingly common.And MASI is one of the leaders in the field. It is also one of the two top players in the pulse oximetry sector. These are devices that check the oxygen saturation level a person's blood. Hospitals use these a great deal and generally the contracts run on a five-year basis, so income is steady and once they're in place it's unlikely the hospitals will switch over to a new type of unit, so there are solid competitive moats.MASI is up almost 44% in the past 12 months, and much of that has come in 2019. This is the kind of company that can grow with the market regardless of what U.S. healthcare ends up looking like.Source: Shutterstock Ionis Pharmaceuticals (IONS)Ionis Pharmaceuticals (NASDAQ:IONS) was founded by leading biotech scientists to expand the use of antisense therapy. It's a new form of treatment that is at the cutting edge of science medicine.Basically, if you can find a genetic marker for a disease, you can synthesize a strand of RNA that can render that gene inactive, so it doesn't reproduce. The potential uses extend to cancers, heart disease, diabetes, asthma, arthritis … the list goes on. * 6 Chinese Stocks That Could Pop On a Trade Deal This technology has the potential to help both rare and common maladies, many of which don't have current effective treatments.IONS is already partnered with a number of larger pharmaceutical firms and is up 55% in the past year, with plenty of headroom left.Source: Shutterstock Osiris Therapeutics (OSIR)Osiris Therapeutics (NASDAQ:OSIR) has a market cap around $650 million, so it's in that perfect spot where it has the potential for big growth on its own, or it could be a target for takeover at a nice premium for a larger pharma looking for a unique product line.OSIR specializes in regenerative medicine products. What that means is, it uses stem cells to build medicines that help everything from wound healing to bone marrow graft acceptance. It's a unique space that has significant possibilities now and for the future.It currently has five products on the market that are focused on wound healing, ligament repairs and surgical wraps on tissues. All promote better healing outcomes with less infections than traditional methods.Last quarter it sold the rights to one of its top stem cell drug for $100 million, so it's work is being recognized. OSIR stock is up 141% for the year and 40% in 2019.Source: Shutterstock Ensign Group (ENSG)Ensign Group (NASDAQ:ENSG) specializes in post-acute care staffing for a wide variety of facilities that would need these services. Some of the most obvious would be assisted living facilities, home health care, rehab facilities and hospice. It manages 250 companies in more than 12 states, around the U.S.This is precisely the sort of sector that will be in huge demand in coming years. While all the technology and new drugs are great, there will still need to be qualified people helping support the patients as they recover and attempt to maintain active lifestyles. * 10 Retirement Stocks That Won't Wilt in a Bear Market It continues to expand its base in California, where the company is headquartered, having just bought another company in Southern California. But its operations beyond the state show that it has what it takes to expand its model where the most opportunity is.Up 59% in the past year, its size makes it a potential takeover target or a big grower on its own.Source: Shutterstock Genomic Health (GHDX)Genomic Health (NASDAQ:GHDX) specializes in genomic diagnostic testing, specifically for cancer. The testing allows for patients and doctors to create individualized treatment strategies for patients.This is important because it means patients get the treatment they need -- they're not over-treated or under-treated. And that is good for the whole healthcare system as well as the patients.Again, this kind of diagnostic tool will be something that insurers, hospitals and patients can get behind since it allows care to better suited to each patient with the goal of lowering costs and improving outcomes.The stock is up over 38% in the past year and it's still going strong.Source: Shutterstock National Research Corp (NRC)National Research (NASDAQ:NRC) is all about delivering all the best possible outcomes for patients with their healthcare providers. NRC sees the current and future healthcare sector as patient-driven, and that is not the traditional model.The patient wasn't much more than a bundle of symptoms that were inserted into the healthcare machines to get repaired and sent back out into the world before. Now, it's about creating an experience that not only serves the patient better, but is able to deliver better outcomes and fewer return visits. It's looking at numbers that view the system more holistically.And NRC provides those numbers from its research. * 7 Cloud Stocks to Buy on Overcast Days While it has been around since 1981, NRC is just coming into its own. And it would be a great takeover target for one of the big healthcare insurers or a large hospital chain.Up 26% in the past year, NRC also delivers a nearly a 2% dividend.Source: Shutterstock AngioDynamics (NASDAQ:ANGO) is a medical device company that specializes in equipment that's used for vascular access, surgery, vascular disease and oncology. It actually made a new acquisition earlier this year to increase its oncology suite of products.Specialty medical device makers are in particular demand globally, since the good ones tend to get most of the business. Medicine is a very conservative practice and tested and true is much more preferable to new and interesting.And generally that's the view from hospitals, insurers and patients. It takes years to put new equipment in place and generally the new equipment is from a trusted equipment maker and not the kid on the block. Having been around since 1988, ANGO fits that bill.Although its global potential looks huge as China looks to upgrade its entire healthcare system, it's been volatile over the last year and relatively flat (actually down .3%). Most of the volatility is trade war related and that can't last forever.Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Low-Priced Tech Stocks With Great Potential * 9 Stocks That Would Be Hurt By a Mexico/U.S. Border Closure * The Era of Car Ownership Is Over. And These 4 Charts Prove It Compare Brokers The post 7 A-Rated Healthcare Stocks for Industry Expansion appeared first on InvestorPlace.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of GHDX earnings conference call or presentation 7-May-19 8:30pm GMT

    Q1 2019 Genomic Health Inc Earnings Call

  • Genomic Health's Strong Growth Spooks Investors
    Motley Foollast month

    Genomic Health's Strong Growth Spooks Investors

    A good start to the year and no increased guidance mean slower growth ahead.

  • Were Invitae's Quarterly Results Really That Bad?
    Motley Foollast month

    Were Invitae's Quarterly Results Really That Bad?

    Sales slipped from the fourth quarter, but there's still a lot to like about this company.

  • Here's Why Shares of Genomic Health Dropped Today
    Motley Foollast month

    Here's Why Shares of Genomic Health Dropped Today

    After Genomic's stellar first quarter, investors are getting jittery about growth in the second half.

  • Genomic Health, Inc. (NASDAQ:GHDX) Delivered A Weaker ROE Than Its Industry
    Simply Wall St.last month

    Genomic Health, Inc. (NASDAQ:GHDX) Delivered A Weaker ROE Than Its Industry

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! While some investors are already well versed in financial metrics (hat tip), this article is for thos...

  • Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Up
    Zackslast month

    Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Up

    Genomic Health (GHDX) registers strong year-over-year growth in revenues on solid domestic and overseas performances.

  • Genomic Health Inc (GHDX) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    Genomic Health Inc (GHDX) Q1 2019 Earnings Call Transcript

    GHDX earnings call for the period ending March 31, 2019.

  • Associated Presslast month

    Genomic Health: 1Q Earnings Snapshot

    On a per-share basis, the Redwood City, California-based company said it had profit of 34 cents. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

  • Here’s What Hedge Funds Think About Genomic Health, Inc. (GHDX)
    Insider Monkey2 months ago

    Here’s What Hedge Funds Think About Genomic Health, Inc. (GHDX)

    We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of December 31st. In this article we look at what those investors think of Genomic Health, Inc. (NASDAQ:GHDX). Is Genomic Health, […]

  • Genomic Health (GHDX) Earnings Expected to Grow: Should You Buy?
    Zacks2 months ago

    Genomic Health (GHDX) Earnings Expected to Grow: Should You Buy?

    Genomic Health (GHDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • 3 Medical Product Stocks Set to Beat This Earnings Season
    Zacks2 months ago

    3 Medical Product Stocks Set to Beat This Earnings Season

    The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.

  • 3 High-Growth Stocks That Are Just Getting Started
    Motley Fool2 months ago

    3 High-Growth Stocks That Are Just Getting Started

    Find out how these companies have positioned themselves for bigger gains.

  • ETF Trends2 months ago

    Four Companies Could Power The New Genomics ETF

    Earlier this week, the Global X Genomics & Biotechnology ETF (Nasdaq: GNOM) debuted, giving investors a new avenue for tapping the fast-growing genomics market. GNOM tracks the Solactive Genomics Index ...

  • Introducing Genomic Health (NASDAQ:GHDX), The Stock That Zoomed 151% In The Last Five Years
    Simply Wall St.2 months ago

    Introducing Genomic Health (NASDAQ:GHDX), The Stock That Zoomed 151% In The Last Five Years

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make fa...

  • The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
    Zacks3 months ago

    The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink

    The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink

  • Genomic Health's New Positive Data to Boost Test Uptake
    Zacks3 months ago

    Genomic Health's New Positive Data to Boost Test Uptake

    Genomic Health (GHDX) continues to see positive developments for Oncotype DX Breast Recurrence Score tests.

  • 4 Small Biotech Stocks Likely to Witness More Upside in 2019
    Zacks3 months ago

    4 Small Biotech Stocks Likely to Witness More Upside in 2019

    The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.

  • 8 Genomic Testing Stocks That Can Ease the Sting of Theranos
    InvestorPlace3 months ago

    8 Genomic Testing Stocks That Can Ease the Sting of Theranos

    Investment scams are nothing new. But since the dot-com bust of 2000, most investors have been able to spot the most egregious, misleading of corporate pitches.That's what's made the Theranos debacle such a shock. The blood-testing company looked, felt and sounded like the real deal. CEO Elizabeth Holmes seemed remarkably credible too… credible enough that insurers, pharmacies and grocery stores were all willing to partner with Theranos.The whole thing, however, was an incredible scam. The company's blood-based tests, as it turns out, couldn't do what Holmes had for years claimed they could. Their results were misleading at best and dangerously wrong at worst. Theranos is no defunct.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNot surprisingly, Theranos' scandal has made investors skeptical of many similar diagnostic companies. * 7 Reasons to Buy Housing Stocks in 2019 That need not be the case, however. Theranos was the exception to the norm rather than the norm. There are many legitimate diagnostic companies, and one area that's seeing a huge boom is genomic testing. Genomic testing stocks belong to companies that look a person's -- or cancer's -- specific gene sequence in order to diagnose and treat patients. Here's a look at eight of the best of them. Exact Sciences (EXAS)Source: Shutterstock Exact Sciences (NASDAQ:EXAS) is committed to treating cancer by spotting it before it forms. Through its partnership with the Mayo Clinic, the company has developed diagnostic tools that can spot concerning colon cancer biomarkers from even the smallest DNA samples, identifying how vulnerable a particular person may be to cancer. In fact, you may be more familiar with the company than you realize. Exact Sciences is the name behind Cologuard, the colon-cancer screener that can be used at home rather than at a doctor's office of medical lab.Exact Sciences isn't yet profitable, but it's also not stopping at colon cancer. It's also working on screening tests that could identify liver, lung, breast and pancreatic cancers. More marketable tests means more revenue, which pushes the company closer to profitability. Genomic Health (GHDX)Source: Shutterstock Genomic Health (NASDAQ:GHDX) is arguably one of the quintessential genomic testing stocks. The company's Oncotype IQ tests allow doctors and caregivers to look at the specific nuances of a particular patient's cancer and tailor a specific treatment plan for that individual. More important, it works. And the medical community believes in what the company brings to the table.At this week's Gallen International Breast Cancer Conference, Dr. Joseph Gligorov of the Breast Cancer Expert Center at the APHP-Tenon Hospital in Paris commented:"The practice-changing precision made possible by such a test can lead to improved quality of care and survival among breast cancer patients, as well as reduced waste of healthcare resources by directing chemotherapy only to patients who have a high likelihood of deriving substantial benefit." * 3 Gold Stocks That Should Glitter With Rising Gold Prices So far the Oncotype battery is limited to breast, prostate and colon cancers, but more forms of cancer are on the radar. In the meantime, Genomic Health continues to refine its existing, proven tests. Sarepta Therapeutics (SRPT)Source: Shutterstock Sarepta Therapeutics (NASDAQ:SRPT) isn't exactly at home in a list of genomic testing stocks in that it's actually the developer of a treatment for Duchenne muscular dystrophy. Its therapy is gene-based, however, making the company more than relevant to investors that believe in the power of gene therapy. Its core product is Exondys 51 -- an injection that can cause a cell to 'skip' a faulty exon in RNA when replicating itself, restoring dystrophin production to functional levels. Dystrophin is a protein needed to make muscles function properly.Sarepta isn't stopping there, however. It's also working on an LGMD gene therapy that Janney analyst Yun Zhong has high hopes for. Zhong, in fact, believes Sarepta could double the size of the exon-skipping market by 2020. Crispr Therapeutics (CRSP)Source: Shutterstock Fans and followers of biotech developments have almost certainly heard the term 'CRISPR,' which is short for 'clustered regularly interspaced short palindromic repeats.' It's a family of DNA sequences that allow researchers and drug developers to manipulate longer spans of genetic material rather than repair one small segment of genetic material. Crispr Therapeutics (NASDAQ:CRSP) is one of the names that helped usher in the new way of thinking about gene-editing. Like Sarepta Therapeutics, it's arguably a little out of place in a look at genomic testing stocks to consider. But the biopharma outfit represents the best of the potential the industry sees for itself as it learns more about how DNA works (and doesn't work). * 10 Tech Stocks With Key Products That Face an Uncertain Future Crispr Therapeutics has already put the idea to good use too. Its pipeline includes treatments for hemoglobinopathies, some cancers, diabetes and other genetic diseases. InVitae (NVTA)InVitae (NYSE:NVTA) isn't exactly a household name, but perhaps someday it will be. The company makes a variety of genomics-based tests that help patients pinpoint potential problem ranging from heart trouble to cancer risks to neurological issues, just to name a few.And customers are buying them up, in spades. Last quarter's top line was up a whopping 117% year-over-year, with unit sales growing more than 100%.InVitae is still logging losses, but they're shrinking, and they're improving at an increasingly faster clip. This year's projected loss of $1.78 per share is only modestly better than last year's loss of $1.94 per share of NVTA stock. But, that loss is expected to be whittled down to only $1.15 per share next year -- on strong double-digit sales growth.InVitae is arguably the name investors are errantly looking past. Illumina (ILMN)Source: Flickr Whereas InVitae is the red-hot name few people have heard of, Illumina (NASDAQ:ILMN) is one of the genomic testing stocks most investors have heard of. The $45 billion behemoth is not only the name that's impossible to avoid, it's been largely deemed as the industry's standard-bearer. Illumina, in simplest terms, makes gene-sequencing and array technologies that can be utilized by drug developers or diagnostic companies. It's powering the genomic-testing market forward by empowering others. * Is This Overlooked Marijuana Stock a Buy? It's also, unlike most of its genomic-focused peers, profitable. Last quarter's revenue may have only grown 11% year-over-year. But, that top line of $867 million translated into earnings of $1.32 per share. For the full year, Illumina banked a profit of $5.72, which is expected to swell to $6.53 this year and $7.50 per share next year. Veracyte (VCYT)Source: Shutterstock Veracyte (NASDAQ:VCYT) currently offers three genomic tests. Afirma helps pin down thyroid cancers, Percepta helps doctors take aim at lung cancer and Envisia aids in the diagnosis of idiopathic pulmonary fibrosis. Like InVitae, Veracyte isn't yet profitable. But, also like InVitae, strong sales growth is quickly chipping away at its losses. Last year's loss of 62 cents per share is expected to shrink to a loss of only 41 cents per share of VCYT stock this year, and shrink to only 23 cents per share next year.Real profits are in sight, even if only on the distant horizon. Myriad Genetics (MYGN)Source: Shutterstock Finally, add Myriad Genetics (NASDAQ:MYGN) to a list of genomic testing stocks to consider. Myriad Genetics appropriately offers a myriad of genomic tests that can help patients and doctors look for genetic markers for everything ranging from breast cancer to depression to arthritis and more.And, like Illumina, Myriad Genetics is profitable. The $2.5 billion outfit turned $217 million worth of revenue last quarter, up 15%, into income of $6.1 million. Its hereditary cancer screener led the way. * The 7 Best Penny Stocks to Buy Growth appears to be in the cards too… perhaps much more than most investors fully appreciate. The medical community is fast-becoming a believer in the power of genetic testing, with the American Society of Breast Surgeons now recommending genetic testing for all breast cancer patients. Meanwhile, Medicare now covers Myriad's myPath(r) Melanoma test.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site,, or follow him on Twitter, at @jbrumley.Compare Brokers The post 8 Genomic Testing Stocks That Can Ease the Sting of Theranos appeared first on InvestorPlace.